Research Papers:

18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer

Ana E. Brito, Allan Santos, André Deeke Sasse, Cesar Cabello, Paulo Oliveira, Camila Mosci, Tiago Souza, Barbara Amorim, Mariana Lima, Celso D. Ramos and Elba Etchebehere _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:36001-36011. https://doi.org/10.18632/oncotarget.16418

Metrics: PDF 1489 views  |   HTML 1804 views  |   ?  


Ana E. Brito1, Allan Santos1,2, André Deeke Sasse3, Cesar Cabello4, Paulo Oliveira5, Camila Mosci1, Tiago Souza1, Barbara Amorim1, Mariana Lima1,2, Celso D. Ramos1,2, Elba Etchebehere1,2

1Nuclear Medicine Division, Campinas State University (UNICAMP), SP, Brazil

2MND Campinas, Campinas, SP, Brazil

3Department of Internal Medicine, Campinas State University (UNICAMP), SP, Brazil

4Department of Gynecology and Obstetrics, Campinas State University (UNICAMP), SP, Brazil

5Department of Statistics, Campinas State University (UNICAMP), SP, Brazil

Correspondence to:

Elba Etchebehere, email: [email protected]

Keywords: fluoride-PET/CT, NaF PET/CT, breast cancer, skeletal tumor burden, bone metastases

Received: February 01, 2017     Accepted: March 14, 2017     Published: March 21, 2017


Purpose: In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease.

Results: Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p < 0.0001) and progression free-survival (p < 0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448).

Materials and Methods: We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months.

Conclusions: 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16418